1. Home
  2. TWIN vs SKYE Comparison

TWIN vs SKYE Comparison

Compare TWIN & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twin Disc Incorporated

TWIN

Twin Disc Incorporated

HOLD

Current Price

$24.90

Market Cap

320.9M

Sector

Industrials

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$1.99

Market Cap

9.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TWIN
SKYE
Founded
1918
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
320.9M
9.0M
IPO Year
1994
2013

Fundamental Metrics

Financial Performance
Metric
TWIN
SKYE
Price
$24.90
$1.99
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$15.00
AVG Volume (30 Days)
92.3K
516.4K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
0.98%
N/A
EPS Growth
1428.57
N/A
EPS
1.86
N/A
Revenue
$381,270,000.00
N/A
Revenue This Year
$10.79
N/A
Revenue Next Year
$8.43
N/A
P/E Ratio
$13.19
N/A
Revenue Growth
11.90
N/A
52 Week Low
$13.02
$0.26
52 Week High
$25.50
$4.99

Technical Indicators

Market Signals
Indicator
TWIN
SKYE
Relative Strength Index (RSI) 53.85 64.80
Support Level $22.13 $0.66
Resistance Level $24.28 $2.32
Average True Range (ATR) 0.97 0.18
MACD 0.08 0.00
Stochastic Oscillator 70.80 51.64

Price Performance

Historical Comparison
TWIN
SKYE

About TWIN Twin Disc Incorporated

Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: